Antibody Discovery & Engineering

The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.

Our process starts with listening to your project needs and then strategically devising a customized scope of work to deliver your next panel of molecules. Whether you need an IgG, scFv, Fab, VHH, or multiple formats, our experienced technical teams and leadership partner with you to help fulfill your needs with the right molecules that demonstrate the desired function, selectivity, and cross-reactivity. Optimal, high-quality and accelerated antibody discovery workflows are available in the following technology platforms: hybridoma, single B cell with the Beacon system, phage display, and yeast display. Our integrated services include immunizations, panning and screening, cloning, NGS and Sanger sequencing, sequence diversity and therapeutic developability analysis, humanization, and affinity maturation.

 

Client Testimonial: Tri-Institutional Therapeutics Discovery Institute and LakePharma (now part of Curia): A Partnership in Antibody Discovery to Enable Innovative Therapeutics

Download a free eBook: Introduction to Hybridoma Technologies for Antibody Discovery

PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery webinar recording available NOW!
Discovery of Potent, Functional Anti-BTLA, and Anti-TIGIT Monoclonal Antibodies using Hybridoma and Phage Display Platform webinar recording available NOW.

Click here to download our Pentamice Flyer

Download the Antibody Discovery & Engineering Services Brochure here.

Customer Testimonial

“LakePharma (now part of Curia) is nothing short of a true partner with Apollos Diagnostics. We will continue to work with Curia as a partner for all of our future antibody development campaigns.”
– John Alderete, Ph.D., MBA; Founder and President of Folium Biomed, LLC
View the testimonial here

“LakePharma (now part of Curia) is a great partner to work with. Their expertise enables them to generate large panels of antibodies that can be used as the foundation for our therapeutic candidates”
– Ronald Herbst, Ph.D., CSO, Pyxis Oncology
View Pyxis clinical pipeline

“LakePharma (now part of Curia) was a great partner; very helpful, focused, and committed. Thank you for your antibody engineering and production services which made this project a success.”
– Maria Day, ImmuNext
View their press release here